In a phase III clinical trial on patients with locally advanced unresectable non-small-cell lung cancer, progression-free survival was significantly extended under consolidation therapy with durvalumab, an anti-PD-L1 mAb, after concurrent chemoradiotherapy relative to a placebo [55]. Here, CD274 is linked to non-small cell lung carcinoma.